{"url_path":"/sec/enta/10-q/2026/item-4","section_key":"item-4","section_title":"Item 4 CONTROLS AND PROCEDURES","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/1177648/0001193125-26-220572-index.html","accession_number":"0001193125-26-220572","cik":"0001177648","ticker":"ENTA","issuer_name":"ENANTA PHARMACEUTICALS INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1177648/0001193125-26-220572-index.html","primary_entity_key":"0001177648","primary_entity_name":"ENANTA PHARMACEUTICALS INC"},"word_count":184,"has_tables":true,"body_markdown":"ITEM 4. CONTROLS AND PROCEDURES\n\nDisclosure Controls and Procedures and Internal Control over Financial Reporting\n\nEvaluation of Disclosure Controls and Procedures.\n\nOur management, with the participation of the principal executive officer and principal financial officer, has evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act), as of the end of the period covered by this quarterly report. Based on this evaluation, the principal executive officer and principal financial officer concluded that these disclosure controls and procedures are effective and designed to ensure that the information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the requisite time periods.\n\nChanges in Internal Control Over Financial Reporting.\n\nThere were no changes in our internal control over financial reporting that occurred during the three months ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.\n\nPART II —OTHER INFORMATION"}